Sebi’s board will discuss revamping mutual fund fee structures to enhance transparency and cost-efficiency for investors. Proposals include reducing total expense ratios and brokerage fees, alongside simplifying IPO disclosures and easing pre-IPO lock-in rules. The regulator aims to make investment more accessible and affordable for the public.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,